Archives of Physical Medicine and Rehabilitation
Volume 88, Issue 5 , Pages 646-652, May 2007

Reliability and Validity of the Incontinence Quality of Life Questionnaire in Patients With Neurogenic Urinary Incontinence

  • Brigitte Schurch, MD

      Affiliations

    • Spinal Cord Injury Center, University Hospital Balgrist, Zurich, Switzerland
    • Corresponding Author InformationReprint requests to Brigitte Schurch, MD, Spinal Cord Injury Center, University Hospital Balgrist, Forchstr 340, CH-8008 Zurich, Switzerland
  • ,
  • Pierre Denys, MD

      Affiliations

    • Hôpital Raymond Poincaré, Garches, Paris, France
  • ,
  • Chris M. Kozma, PhD

      Affiliations

    • independent research consultant and University of South Carolina, Columbia, SC
  • ,
  • Pat Ray Reese, PhD

      Affiliations

    • Reese Associates Consulting LLC, Cary, NC
  • ,
  • Terra Slaton, MS

      Affiliations

    • independent research consultant, West Columbia, South Carolina
  • ,
  • Rich Barron, MS

      Affiliations

    • Allergan Inc, Irvine, CA.

Abstract 

Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron R. Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence.

Objective

To assess the reliability, validity, responsiveness, and minimally important difference (MID) of the Incontinence Quality of Life (I-QOL) questionnaire in patients with urinary incontinence due to neurogenic detrusor overactivity.

Design

Randomized, double-blind, multicenter, placebo-controlled study.

Setting

Eight centers across Belgium, France, and Switzerland.

Participants

Patients with urinary incontinence due to neurogenic detrusor overactivity inadequately managed on oral anticholinergics. Fifty-nine patients (spinal cord injury, n=53; multiple sclerosis, n=6) were enrolled.

Intervention

Single dose of botulinum toxin type A (Botox) (200 or 300U) or placebo.

Main Outcome Measures

I-QOL questionnaire completed at screening and over a 24-week post-treatment period.

Results

The Cronbach α ranged from .79 to .93, indicating that I-QOL is a reliable measure of QOL in neurogenic urinary incontinence patients. No item had more than 5.1% missing or out of range values. With the exception of 2 items, questions showed acceptable item-scale correlation and scaling success results varied by domain. Post-treatment correlations indicated acceptable construct validity. The I-QOL was responsive to improvements in symptoms. MID values ranged from 4 to 11 points.

Conclusions

Results suggest that I-QOL is a reliable, valid, and responsive measure of incontinence-related QOL in neurogenic patients.

Key Words: Bladder, neurogenic, Botulinum toxin type A, Quality of life, Rehabilitation, Reliability and validity, Urinary incontinence

 

 Supported by Allergan Inc.

 A commercial party having a direct financial interest in the results of the research supporting this article has conferred or will confer a financial benefit upon 1 or more of the authors. Kozma, Reese, and Slaton are paid consultants to Allergan. Barron was an employee of Allergan at the time of the research.

PII: S0003-9993(07)00106-2

doi:10.1016/j.apmr.2007.02.009

Archives of Physical Medicine and Rehabilitation
Volume 88, Issue 5 , Pages 646-652, May 2007